Low-normal thyroid function and the pathogenesis of common cardio-metabolic disorders

European Journal of Clinical Investigation

Volumn 45, Issue 5, 2015, Pages 494-503

  van Tienhoven Wind, Lynnda J N ^a   Dullaart, Robin P F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cardiovascular disease; Chronic kidney disease; Lipids; Low normal thyroid function; Metabolic syndrome; Nonalcoholic fatty liver disease; Obesity; Thyroid hormones; Thyroid stimulating hormone

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THYROID HORMONE; TRIACYLGLYCEROL; THYROTROPIN; THYROXINE;

ARTICLE; BASIC RESEARCH; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; FATTY LIVER; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INSULIN RESISTANCE; LIPID HOMEOSTASIS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MEDLINE; METABOLIC DISORDER; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBSERVATIONAL STUDY; PATHOGENESIS; POSTMENOPAUSE; PRIORITY JOURNAL; SUBCLINICAL HYPOTHYROIDISM; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); THYROID FUNCTION; ASYMPTOMATIC DISEASE; CHRONIC KIDNEY FAILURE; METABOLISM; RISK FACTOR; THYROID GLAND;

ASYMPTOMATIC DISEASES; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; HUMANS; HYPOTHYROIDISM; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; THYROID GLAND; THYROTROPIN; THYROXINE; TRIGLYCERIDES;

EID: 84928359572     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12423     Document Type: Article

References (98)

1. Taylor PN, Razvi S, Pearce SH, Dayan CM. Clinical review: a review of the clinical consequences of variation in thyroid function within the reference range. J Clin Endocrinol Metab 2013;98:3562-71.
2. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001;344:501-9.
3. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev 2008;29:76-131.
4. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med 2000;160:526-34.
5. Aoki Y, Belin RM, Clickner R, Jeffries R, Phillips L, Mahaffey KR. Serum TSH and total T4 in the United States population and their association with participant characteristics: National Health and Nutrition Examination Survey (NHANES 1999-2002). Thyroid 2007;17:1211-23.
6. Andersen S, Pedersen KM, Bruun NH, Laurberg P. Narrow individual variations in serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical thyroid disease. J Clin Endocrinol Metab 2002;87:1068-72.
7. Walsh JP. Setpoints and susceptibility: do small differences in thyroid function really matter? Clin Endocrinol (Oxf) 2011;75:158-9.
8. Ochs N, Auer R, Bauer DC, Nanchen D, Gussekloo J, Cornuz J et al. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med 2008;148:832-45.
9. Razvi S, Shakoor A, Vanderpump M, Weaver JU, Pearce SH. The influence of age on the relationship between subclinical hypothyroidism and ischemic heart disease: a meta-analysis. J Clin Endocrinol Metab 2008;93:2998-3007.
10. Singh S, Duggal J, Molnar J, Maldonado F, Barsano CP, Arora R. Impact of subclinical thyroid disorders on coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis. Int J Cardiol 2008;125:41-8.
11. de Groot E, Hovingh GK, Wiegman A, Duriez P, Smit AJ, Fruchart JC et al. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis: review. Circulation 2004;23(Suppl 1):III33-8.
12. Nagasaki T, Inaba M, Henmi Y, Kumeda Y, Ueda M, Tahara H et al. Decrease in carotid-intima media thickness in hypothyroid patients after normalization of thyroid function. Clin Endocrinol (Oxf) 2003;59:607-12.
13. Völzke H, Robinson DM, Schminke U, Lüdemann J, Rettig R, Felix SB et al. Thyroid function and carotid wall thickness. J Clin Endocrinol Metab 2004;89:2145-9.
14. Jorde R, Joakimsen O, Stensland E, Mathiesen EB. Lack of significant association between intima-media thickness in the carotid artery and serum TSH level. The Tromsø Study. Thyroid 2008;18:21-5.
15. Gao N, Zhang W, Zhang YZ, Yang Q, Chen SH. Carotid intima-media thickness in patients with subclinical hypothyroidism: a meta-analysis. Atherosclerosis 2013;227:18-25.
16. Asvold BO, Bjøro T, Platou C, Vatten LJ. Thyroid function and the risk of coronary heart disease: 12-year follow-up of the HUNT study in Norway. Clin Endocrinol (Oxf) 2012;77:911-7.
17. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 2001;358:861-5.
18. Dullaart RPF, de Vries R, Roozendaal C, Kobold AC, Sluiter WJ. Carotid artery intima media thickness is inversely related to serum free thyroxine in euthyroid subjects. Clin Endocrinol (Oxf) 2007;67:668-73.
19. Takamura N, Akilzhanova A, Hayashida N, Kadota K, Yamasaki H, Usa T et al. Thyroid function is associated with carotid intima-media thickness in euthyroid subjects. Atherosclerosis 2009;204:e77-81.
20. Danese MD, Ladenson PW, Meinert CL, Powe NR. Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J Clin Endocrinol Metab 2000;85:2993-3001.
21. Duntas LH. Thyroid disease and lipids. Thyroid 2002;12:287-93.
22. Dullaart RPF, van Doormaal JJ, Hoogenberg K, Sluiter WJ. Triiodothyronine rapidly lowers plasma lipoprotein (a) in hypothyroid subjects. Neth J Med 1995;46:179-84.
23. Roos A, Bakker SJ, Links TP, Gans RO, Wolffenbuttel BH. Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. J Clin Endocrinol Metab 2007;92:491-6.
24. Kim BJ, Kim TY, Koh JM, Kim HK, Park JY, Lee KU et al. Relationship between serum free T4 (FT4) levels and metabolic syndrome (MS) and its components in healthy euthyroid subjects. Clin Endocrinol (Oxf) 2009;70:152-60.
25. Park HT, Cho GJ, Ahn KH, Shin JH, Hong SC, Kim T et al. Thyroid stimulating hormone is associated with metabolic syndrome in euthyroid postmenopausal women. Maturitas 2009;62:301-5.
26. de Jesus Garduño-Garcia J, Alvirde-Garcia U, López-Carrasco G, Padilla Mendoza ME, Mehta R, Arellano-Campos O et al. TSH and free thyroxine concentrations are associated with differing metabolic markers in euthyroid subjects. Eur J Endocrinol 2010;163:273-8.
27. Lee YK, Kim JE, Oh HJ, Park KS, Kim SK, Park SW et al. Serum TSH level in healthy Koreans and the association of TSH with serum lipid concentration and metabolic syndrome. Korean J Intern Med 2011;26:432-9.
28. Lu L, Wang B, Shan Z, Jiang F, Teng X, Chen Y et al. The correlation between thyrotropin and dyslipidemia in a population-based study. J Korean Med Sci 2011;26:243-9.
29. Wang C, Zhang X, Zhao Y, Song X, Zhang B, Guan Q et al. Thyroid-Stimulating Hormone Levels within the Reference Range Are Associated with Serum Lipid Profiles Independent of Thyroid Hormones. J Clin Endocrinol Metab 2012;97:2724-31.
30. Shin DJ, Osborne TF. Thyroid hormone regulation and cholesterol metabolism are connected through Sterol Regulatory Element-Binding Protein-2 (SREBP-2). J Biol Chem 2003;278:34114-8.
31. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009;50(Suppl):S172-7.
32. Chan DC, Lambert G, Barrett PH, Rye KA, Ooi EM, Watts GF. Plasma proprotein convertase subtilisin/kexin type 9: a marker of LDL apolipoprotein B-100 catabolism? Clin Chem 2009;55:2049-52.
33. Kwakernaak AJ, Lambert G, Muller Kobold AC, Dullaart RPF. Adiposity blunts the positive relationship of thyrotropin with proprotein convertase subtilisin-kexin type 9 levels in euthyroid subjects. Thyroid 2013;23:166-72.
34. Tian L, Song Y, Xing M, Zhang W, Ning G, Li X et al. A novel role for thyroid-stimulating hormone: up-regulation of hepatic 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase expression through the cyclic adenosine monophosphate/protein kinase A/cyclic adenosine monophosphate-responsive element binding protein pathway. Hepatology 2010;52:1401-9.
35. Gälman C, Bonde Y, Matasconi M, Angelin B, Rudling M. Dramatically increased intestinal absorption of cholesterol following hypophysectomy is normalized by thyroid hormone. Gastroenterology 2008;134:1127-36.
36. Eshraghian A, Hamidian Jahromi A. Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review. World J Gastroenterol 2014;20:8102-9.
37. Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006;49:755-65.
38. Adiels M, Olofsson SO, Taskinen MR, Borén J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008;28:1225-36.
39. Moon JH, Kim HJ, Kim HM, Choi SH, Lim S, Park YJ et al. Decreased expression of hepatic low-density lipoprotein receptor-related protein 1 in hypothyroidism: a novel mechanism of atherogenic dyslipidemia in hypothyroidism. Thyroid 2013;23:1057-65.
40. Van Tienhoven-Wind LJN, Dullaart RPF. Low normal thyroid function as a determinant of increased large very low density lipoprotein particles. Clin Biochem 2015; doi: 10.1016/j.clinbiochem.2015.01.015 [Epub ahead of print].
41. Dullaart RPF, Hoogenberg K, Groener JE, Dikkeschei LD, Erkelens DW, Doorenbos H. The activity of cholesteryl ester transfer protein is decreased in hypothyroidism: a possible contribution to alterations in high-density lipoproteins. Eur J Clin Invest 1990;20:581-7.
42. Valdemarsson S. Plasma lipoprotein alterations in thyroid dysfunction. Roles of lipoprotein lipase, hepatic lipase and LCAT. Acta Endocrinol Suppl (Copenh) 1983;255:1-52.
43. Tan KC, Shiu SW, Kung AW. Effect of thyroid dysfunction on high-density lipoprotein subfraction metabolism: roles of hepatic lipase and cholesteryl ester transfer protein. J Clin Endocrinol Metab 1998;83:2921-4.
44. Dallinga-Thie GM, Dullaart RPF, van Tol A. Concerted actions of cholesteryl ester transfer protein and phospholipid transfer protein in type 2 diabetes: effects of apolipoproteins. Curr Opin Lipidol 2007;18:251-7.
45. Dullaart RPF, Dallinga-Thie GM, Wolffenbuttel BH, van Tol A. CETP inhibition in cardiovascular risk management: a critical appraisal. Eur J Clin Invest 2007;37:90-8.
46. de Vries R, Perton FG, Dallinga-Thie GM, van Roon AM, Wolffenbuttel BH, van Tol A et al. Plasma cholesteryl ester transfer is a determinant of intima-media thickness in type 2 diabetic and nondiabetic subjects: role of CETP and triglycerides. Diabetes 2005;54:3554-9.
47. Kappelle PJ, Perton F, Hillege HL, Dallinga-Thie GM, Dullaart RPF. High plasma cholesteryl ester transfer but not CETP mass predicts incident cardiovascular disease: a nested case-control study. Atherosclerosis 2011;217:249-52.
48. Triolo M, Kwakernaak AJ, Perton FG, de Vries R, Dallinga-Thie GM, Dullaart RPF. Low normal thyroid function enhances plasma cholesteryl ester transfer in Type 2 diabetes mellitus. Atherosclerosis 2013;228:466-71.
49. Triolo M, Annema W, Dullaart RPF, Tietge UJ. Assessing the functional properties of high-density lipoproteins: an emerging concept in cardiovascular research. Biomark Med 2013;7:457-72.
50. Sundaram V, Hanna AN, Koneru L, Newman HA, Falko JM. Both hypothyroidism and hyperthyroidism enhance low density lipoprotein oxidation. J Clin Endocrinol Metab 1997;82:3421-4.
51. Diekman T, Demacker PN, Kastelein JJ, Stalenhoef AF, Wiersinga WM. Increased oxidizability of low-density lipoproteins in hypothyroidism. J Clin Endocrinol Metab 1998;83:1752-5.
52. Cebeci E, Alibaz-Oner F, Usta M, Yurdakul S, Erguney M. Evaluation of oxidative stress, the activities of paraoxonase and arylesterase in patients with subclinical hypothyroidism. J Investig Med 2012;60:23-8.
53. Torun AN, Kulaksizoglu S, Kulaksizoglu M, Pamuk BO, Isbilen E, Tutuncu NB. Serum total antioxidant status and lipid peroxidation marker malondialdehyde levels in overt and subclinical hypothyroidism. Clin Endocrinol (Oxf) 2009;70:469-74.
54. Ittermann T, Baumeister SE, Völzke H, Wasner C, Schminke U, Wallaschofski H et al. Are serum TSH levels associated with oxidized low-density lipoprotein? Results from the Study of Health in Pomerania. Clin Endocrinol (Oxf) 2012;76:526-32.
55. Triolo M, de Boer JF, Annema W, Kwakernaak AJ, Tietge UJ, Dullaart RPF. Low normal free T4 confers decreased high-density lipoprotein antioxidative functionality in the context of hyperglycaemia. Clin Endocrinol (Oxf) 2013;79:416-23.
56. Nobécourt E, Jacqueminet S, Hansel B, Chantepie S, Grimaldi A, Chapman MJ et al. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia 2005;48:529-38.
57. Waring AC, Rodondi N, Harrison S, Kanaya AM, Simonsick EM, Miljkovic I et al. Thyroid function and prevalent and incident metabolic syndrome in older adults: the Health, Ageing and Body Composition Study. Clin Endocrinol (Oxf) 2012;76:911-8.
58. Laurberg P, Knudsen N, Andersen S, Carlé A, Pedersen IB, Karmisholt J. Thyroid function and obesity. Eur Thyroid J 2012;1:159-67.
59. Kim B. Thyroid hormone as a determinant of energy expenditure and the basal metabolic rate. Thyroid 2008;18:141-4.
60. Knudsen N, Laurberg P, Rasmussen LB, Bülow I, Perrild H, Ovesen L et al. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J Clin Endocrinol Metab 2005;90:4019-24.
61. Kitahara CM, Platz EA, Ladenson PW, Mondul AM, Menke A, Berrington de González A. Body fatness and markers of thyroid function among U.S. men and women. PLoS ONE 2012;7:e34979.
62. Reinehr T, Andler W. Thyroid hormones before and after weight loss in obesity. Arch Dis Child 2002;87:320-3.
63. Maratou E, Hadjidakis DJ, Kollias A, Tsegka K, Peppa M, Alevizaki M et al. Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. Eur J Endocrinol 2009;160:785-90.
64. Stanická S, Vondra K, Pelikánová T, Vlcek P, Hill M, Zamrazil V. Insulin sensitivity and counter-regulatory hormones in hypothyroidism and during thyroid hormone replacement therapy. Clin Chem Lab Med 2005;43:715-20.
65. Iwen KA, Schröder E, Brabant G. Thyroid hormones and the metabolic syndrome. Eur Thyroid J 2013;2:83-92.
66. Handisurya A, Pacini G, Tura A, Gessl A, Kautzky-Willer A. Effects of T4 replacement therapy on glucose metabolism in subjects with subclinical (SH) and overt hypothyroidism (OH). Clin Endocrinol (Oxf) 2008;69:963-9.
67. Cai Y, Ren Y, Shi J. Blood pressure levels in patients with subclinical thyroid dysfunction: a meta-analysis of cross-sectional data. Hypertens Res 2011;34:1098-105.
68. Walsh JP, Bremner AP, Bulsara MK, O'Leary P, Leedman PJ, Feddema P et al. Subclinical thyroid dysfunction and blood pressure: a community-based study. Clin Endocrinol (Oxf) 2006;65:486-91.
69. Jian WX, Jin J, Qin L, Fang WJ, Chen XR, Chen HB et al. Relationship between thyroid-stimulating hormone and blood pressure in the middle-aged and elderly population. Singapore Med J 2013;54:401-5.
70. Bradley SE, Stéphan F, Coelho JB, Réville P. The thyroid and the kidney. Kidney Int 1974;6:346-65.
71. Iglesias P, Díez JJ. Thyroid dysfunction and kidney disease. Eur J Endocrinol 2009;160:503-15.
72. den Hollander JG, Wulkan RW, Mantel MJ, Berghout A. Correlation between severity of thyroid dysfunction and renal function. Clin Endocrinol (Oxf) 2005;62:423-7.
73. Shin DH, Lee MJ, Lee HS, Oh HJ, Ko KI, Kim CH et al. Thyroid hormone replacement therapy attenuates the decline of renal function in chronic kidney disease patients with subclinical hypothyroidism. Thyroid 2013;23:654-66.
74. Briasoulis A, Bakris GL. Chronic kidney disease as a coronary artery disease risk equivalent. Curr Cardiol Rep 2013;15:340.
75. Rhee CM, Kalantar-Zadeh K, Streja E, Carrero JJ, Ma JZ, Lu JL et al. The relationship between thyroid function and estimated glomerular filtration rate in patients with chronic kidney disease. Nephrol Dial Transplant 2015;30:282-7.
76. Asvold BO, Bjøro T, Vatten LJ. Association of thyroid function with estimated glomerular filtration rate in a population-based study: the HUNT study. Eur J Endocrinol 2011;164:101-5.
77. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073-81.
78. Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med 2014;11:e1001680.
79. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006;40:S5-10.
80. Erickson SK. Nonalcoholic fatty liver disease. J Lipid Res 2009;50:S412-6.
81. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013;10:686-90.
82. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002;35:367-72.
83. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341-50.
84. Schindhelm RK, Dekker JM, Nijpels G, Bouter LM, Stehouwer CD, Heine RJ et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn study. Atherosclerosis 2007;191:391-6.
85. Cordeiro A, Souza LL, Einicker-Lamas M, Pazos-Moura CC. Non-classic thyroid hormone signalling involved in hepatic lipid metabolism. J Endocrinol 2013;25:R47-57.
86. Cable EE, Finn PD, Stebbins JW, Hou J, Ito BR, van Poelje PD et al. Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist. Hepatology 2009;49:407-17.
87. Turer AT, Browning JD, Ayers CR, Das SR, Khera A, Vega GL et al. Adiponectin as an independent predictor of the presence and degree of hepatic steatosis in the Dallas Heart Study. J Clin Endocrinol Metab 2012;97:E982-6.
88. Dullaart RPF, van den Berg EH, van der Klauw MM, Blokzijl H. Low normal thyroid function attenuates serum alanine aminotransferase elevations in the context of metabolic syndrome and insulin resistance in white people. Clin Biochem 2014;47:1028-32.
89. Pagadala MR, Zein CO, Dasarathy S, Yerian LM, Lopez R, McCullough AJ. Prevalence of hypothyroidism in nonalcoholic fatty liver disease. Dig Dis Sci 2012;57:528-34.
90. Chung GE, Kim D, Kim W, Yim JY, Park MJ, Kim YJ et al. Non-alcoholic fatty liver disease across the spectrum of hypothyroidism. J Hepatol 2012;57:150-6.
91. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960-7.
92. Targher G, Montagnana M, Salvagno G, Moghetti P, Zoppini G, Muggeo M et al. Association between serum TSH, free T4, and serum liver enzyme activities in a large cohort of unselected outpatients. Clin Endocrinol (Oxf) 2008;68:481-4.
93. Xu C, Xu L, Yu C, Miao M, Li Y. Association between thyroid function and nonalcoholic fatty liver disease in euthyroid elderly Chinese. Clin Endocrinol (Oxf) 2011;75:240-6.
94. Tao Y, Gu H, Wu J, Sui J. Thyroid function is associated with non-alcoholic fatty liver disease in euthyroid subjects. Endocr Res 2014;1-5. [Epub ahead of print].
95. Ittermann T, Haring R, Wallaschofski H, Baumeister SE, Nauck M, Dörr M et al. Inverse association between serum free thyroxine levels and hepatic steatosis: results from the Study of Health in Pomerania. Thyroid 2012;22:568-74.
96. Zhang J, Sun H, Chen L, Zheng J, Hu X, Wang S et al. Relationship between serum TSH level with obesity and NAFLD in euthyroid subjects. J Huazhong Univ Sci Technolog Med Sci 2012;32:47-52.
97. Carulli L, Ballestri S, Lonardo A, Lami F, Violi E, Losi L et al. Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels? Intern Emerg Med 2013;8:297-305.
98. Eshraghian A, Dabbaghmanesh MH, Eshraghian H, Fattahi MR, Omrani GR. Nonalcoholic fatty liver disease in a cluster of Iranian population: thyroid status and metabolic risk factors. Arch Iran Med 2013;16:584-9.